Inflammatory Breast Cancer: a Single Centre Analysis |
Gogia, Ajay
(Medical Oncology Department, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences)
Raina, Vinod (Medical Oncology Department, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) Deo, Suryanarayan Vishnu (Surgical Oncology Department, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) Shukla, Nootan Kumar (Surgical Oncology Department, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) Mohanti, Bidhu Kalyan (Radiation Oncology Department, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) Sharma, Daya Nand (Radiation Oncology Department, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) |
1 | Mamounas EP, Anderson SJ, Dignam JJ, et al (2012). Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol, 32, 3960-66. |
2 | Perez EA, Romond EH, Suman VJ, et al (2011). Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol, 25, 3366-73. |
3 | Slamon D, Eiermann W, Robert N, et al (2011). for the Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med, 14, 1273-83. |
4 | Turpin E, Bieche I, Bertheau P (2002). Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene, 21, 7593-7. DOI |
5 | Harris EE, Schultz D, Bertsch H (2003). Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys, 55, 1200-8. DOI |
6 | Gianni L, Eiermann W, Semiglazov, et al (2010). Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab vs neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 375, 377-84. DOI ScienceOn |
7 | Gianni L, Pienkowski T, Im YH, et al (2012). Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol, 1, 25-32. |
8 | Gianni L, Dafni U, Gelber RD, et al (2011). Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol, 3, 236-44. |
9 | Kaufmann M, Morrow M, von Minckwitz G, et al (2010). Locoregional treatment of primary breast cancer: consensus recommendations from an international expert panel. Cancer, 5, 1184-91. |
10 | Kim T, Lau J, Erban J (2006). Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review. Clin Breast Cancer ,7, 386-95. DOI |
11 | Bear HD, Tang G, Rastogi P, et al (2012). Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med, 4, 310-20. |
12 | Kuerer HM, Newman LA, Smith TL (1999). Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol, 17, 460-69. DOI |
13 | Low JA, Berman AW, Steinberg SM, et al (2004)Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol, 22, 4067-74. DOI |
14 | Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al (2004). Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M.D. Anderson Cancer Center experience. Clin Breast Cancer, 4, 415-9. DOI |
15 | Chevallier B, Asselain B, Kunlin A, et al (1987). Inflammatory breast cancer: Determination of prognostic factors by univariate and multivariate analysis. Cancer, 60, 897-902. DOI |
16 | Classe JM, Bordes V, Campion L, et al (2009). Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol, 5, 726-32. |
17 | Cristofanilli M, Valero V, Buzdar AU, et al (2007). Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer, 110, 1436-41. DOI |
18 | Ellis MJ, Suman VJ, Hoog J, et al (2011). Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol, 17, 2342-49. |
19 | Dawood S, Ueno NT, Valero V, et al (2011). Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer, 117, 1819-23. DOI |
20 | Dawood S, Merajver SD, Viens P, et al (2011). International expert panel on inflammatory breast cancer: Consensus statement for standardized diagnosis and treatment. Ann Oncol, 22, 515-23. DOI |
21 | Baselga J, Bradbury I, Eidtmann H, et al (2012). for the NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 379, 633-40. DOI |
22 | Baldini E, Gardin G, Evagelista G (2004). Long-term results of combined-modality therapy for inflammatory breast carcinoma. Clin Breast Cancer, 5, 358-63. DOI |